Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HypoSti.CAR-HER2 T cells in HER2 Positive Advanced Solid Tumors
NCT05681650Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of HypoSti.CAR-HER2 T cells in HER2-positive solid tumor (HER2+), sponsored by Chinese PLA General Hospital. Started Oct 2023; status: recruiting.
02
Drugs
HypoSti.CAR-HER2 T cells
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT05681650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681650.